Comprehensive mapping of immune tolerance yields a regulatory TNF receptor 2 signature in a murine model of successful Fel d 1‐specific immunotherapy using high‐dose CpG adjuvant

Abstract excerpt

Abstract Background The prevalence of allergy to cat is expanding worldwide. Allergen‐specific immunotherapy (AIT) has advantages over symptomatic pharmacotherapy and promises long‐lasting disease control in allergic patients. However, there is still a need to improve cat AIT regarding efficacy, safety, and adherence to the treatment. Here, we aim to boost immune tolerance to the major cat allergen Fel d 1 by...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Allergic Rhinitis and Sensitization
• Share to Dermatology and Skin Diseases
• Share to Ocular Surface and Contact Lens